Mild cognitive impairment (MCI) describes a condition with the following characteristics:
- Subjective cognitive complaints: The person affected or their family members notice a change.
- Objectively measurable deficits: In standardized tests, the patient performs worse than would be expected given their age and education level.
- Preserved ability to manage daily life: The person can still largely manage daily life independently. Complex activities (managing finances, using new technologies) may already be difficult.
- No dementia: The deficits are not severe enough to warrant a diagnosis of dementia in older adults.
Two subtypes are distinguished: Amnestic MCI is primarily characterized by memory impairments and is most strongly associated with Alzheimer’s disease. Non-amnestic MCI affects other areas such as attention, language, or executive functions.
→ For an overview of dementia disorders: Dementia in older adults.
.jpg "Leichte kognitive Störung (MCI)")
- Prevalence among those over 65: 15 to 20 percent meet the criteria for MCI.
- Prevalence among those over 75: Up to 25 percent.
- Progression to dementia: 10 to 15 percent per year—cumulatively about 50 percent over five years.
- Stable or reversible course: The other half remains stable or returns to normal functioning.
These figures are the most important things patients and their families should know about MCI: It is not a foregone conclusion. It is a clinical category with a varied prognosis that depends heavily on the cause, risk factors, and intervention.
MCI is not a single disease but an umbrella term. The clinical symptoms can stem from a wide variety of causes:
- Alzheimer’s-typical pathology: Beta-amyloid and tau deposits can be detected in about half of MCI patients. This group has the highest risk of conversion. More on this: Alzheimer’s disease.
- Vascular changes: Microcirculatory damage associated with hypertension, diabetes in older adults, and atrial fibrillation in older adults.
- Depression: Particularly common in younger MCI patients—pseudodementia as a subtype. For more information, see: Depression in Older Adults.
- Drug side effects: Benzodiazepines, anticholinergics, opioids, certain antihypertensives—a key issue in polypharmacy in older adults.
- Sleep apnea: Often undiagnosed, it causes significant cognitive symptoms.
- Vitamin B12 deficiency: A classic reversible cause, detectable through laboratory testing—often associated with malnutrition in older adults.
- Thyroid dysfunction: Both hypothyroidism and hyperthyroidism.
- Chronic alcohol use: Relevant in older adults even at moderate levels.
- Normal-pressure hydrocephalus: A rare cause, but one that can sometimes be treated surgically.
Clinically, distinguishing between these causes is crucial: Some are reversible, others are not—and treatment varies depending on the cause.
→ How medications can contribute to cognitive symptoms: Polypharmacy in older adults.
→ Distinguishing between depression and early-stage dementia: Dementia or depression?
Diagnosing MCI is challenging because it requires distinguishing between normal findings, MCI, and early-stage dementia. The standardized evaluation includes:
1. Structured interview
Subjective symptoms, timeline, changes in daily life, family history, medication, pre-existing conditions, psychological stressors. Obtaining a history from family members is essential—many patients downplay their deficits.
2. Neuropsychological testing
- MoCA (Montreal Cognitive Assessment): Sensitive to mild deficits. The gold standard in MCI screening. A score below 26 is suspicious.
- MMSE (Mini-Mental State Examination): Less sensitive for MCI, but widely used.
- DemTect: A German test with good sensitivity for mild impairments.
- Comprehensive neuropsychological testing: To be conducted at specialized centers in cases of uncertainty—covers various cognitive domains in detail.
3. Laboratory
Rule out reversible causes: Complete blood count, TSH, vitamin B12, folic acid, vitamin D, liver and kidney function tests, inflammatory markers, and possibly HIV and syphilis serology.
4. Imaging
MRI or CT to detect vascular lesions, atrophy patterns, hemorrhages, tumors, and normal-pressure hydrocephalus. The typical Alzheimer’s pattern shows hippocampal atrophy. More on structured dementia diagnostics.
5. Biomarkers — the breakthrough of recent years
In cases of clinical uncertainty or prior to treatment decisions:
- Cerebrospinal fluid analysis for beta-amyloid 1-42, total tau, and phospho-tau
- Amyloid-PET or Tau-PET at specialized centers
- Blood-based biomarkers (plasma-based p-Tau217)—validated in studies since 2024, gradually becoming available in routine clinical practice
These biomarkers answer the crucial question: Is Alzheimer’s pathology underlying the MCI or not? The answer changes the prognosis and, if the test is positive, opens up new treatment options.
→ Learn more about comprehensive dementia diagnostics.
Not every case of MCI leads to dementia. The most important prognostic factors:
- Positive amyloid biomarker: Conversion is significantly more likely—with a positive result, approximately 50 percent within three to five years.
- Amnestic MCI: Higher risk of conversion than non-amnestic forms.
- Advanced age: Every year counts.
- ApoE-ε4 genotype: Genetic risk factor—especially with two copies.
- Hippocampal atrophy on MRI: Imaging risk marker.
- Vascular risk factors: Hypertension, diabetes in older adults, smoking — accelerate progression.
- Co-occurring depression, sleep disorders, hearing loss: Modifiable risk factors. Depression in older adults, in particular, is often overlooked and treatable.
MCI is not a time to wait and see. It is the best time to take action. Five points of focus:
1. Address modifiable risk factors
The Lancet Commission on Dementia 2024 identifies 14 modifiable risk factors that together account for about 45 percent of the risk of dementia. The most important ones at the MCI stage:
- Treat high blood pressure (target range determined individually)
- Optimize diabetes management in older adults, but avoid overly aggressive treatment in cases of frailty
- Quit smoking
- Correct hearing loss (provide hearing aids)
- Correct vision problems (glasses, cataract surgery)
- Diagnosing and treating depression in older adults
- Actively address social isolation and loneliness
- Limiting alcohol consumption to moderate amounts
2. Physical Activity
Studies show that aerobic exercise, strength training, and combined programs have protective effects on cognitive function—while also helping to prevent sarcopenia. The recommendation: at least 150 minutes of moderate-intensity activity per week, plus strength training twice a week.
3. Cognitive Stimulation
Structured memory training, Cognitive Stimulation Therapy (CST), and lifelong learning. The effects are moderate but measurable.
4. Diet
The Mediterranean diet and the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) have been shown to have protective effects in cohort studies. Key elements: vegetables, berries, nuts, fish, olive oil, limited red meat, limited sugar. Nutritional deficiencies should be ruled out—for more information, see: Malnutrition in Older Adults.
5. Anti-amyloid therapy — new as of 2024/2025
For MCI with positive amyloid biomarker detection, lecanemab and donanemab are available. Study data (CLARITY-AD, TRAILBLAZER-ALZ 2) show a 27 to 35 percent slowdown in cognitive decline over 18 months. Requirements and limitations:
- Only at specialized centers with the appropriate expertise
- A prerequisite is evidence of amyloid pathology via biomarker detection
- Contraindicated in certain genetic profiles and in cases of microbleeds
- Regular MRI follow-ups due to ARIA (amyloid-related imaging abnormalities)
- Realistic expectations: Slowing of progression, not a cure
→ For details on the new Alzheimer’s therapies: Alzheimer’s Disease and Dementia Treatment.
- Take it seriously without causing alarm: The fear triggered by an MCI diagnosis is often greater than the disease itself. Informed calm is more helpful than dramatized worry.
- Encourage activity: Shared activities, exercise, social engagement—anything that helps the person come out of their shell.
- Arrange end-of-life planning: A living will and power of attorney should be drawn up during the MCI stage, while the person’s legal capacity is still intact.
- Request a medication review: Many cognitive symptoms are medication-related and therefore partially reversible. Structured deprescribing can help.
- Annual follow-up: MCI is a dynamic condition that should be monitored—ideally with structured frailty screening.
Not all forgetfulness is MCI, but the following scenarios warrant a structured evaluation:
- Memory problems that worsen over months
- Difficulty finding the right words that occurs significantly more often
- Difficulty orienting oneself in new or familiar environments
- Difficulty planning and organizing
- Family members notice a change—even if the patient denies it
- Personal distress regarding the cognitive situation
- A combination of forgetfulness and new mood swings—should it be evaluated for dementia or depression?
The first point of contact is the primary care physician, who, if dementia is suspected, will refer the patient to a memory clinic, a neurologist, or a geriatrician. The geriatric perspective is particularly valuable when the situation is multifactorial—medications, falls, nutrition, and social circumstances must all be assessed simultaneously.
→ How a comprehensive geriatric assessment enables this holistic view.
